Status:
UNKNOWN
Use of Ventavis in Patients With Postembolic Residual Pulmonary Hypertension
Lead Sponsor:
Meshalkin Research Institute of Pathology of Circulation
Conditions:
Residual Pulmonary Hypertension
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
To assess the effectiveness of the synthetic analogue of prostacyclin in postembolic residual pulmonary hypertension.
Eligibility Criteria
Inclusion
- Patients with pulmonary embolism after undergone surgical treatment (intravascular thrombolysis, catheter thrombus fragmentation)
- Patients with preserved thromboembolism in the pulmonary circulation system and mean pressure in the pulmonary artery of more than 25 mm Hg
Exclusion
- Patient did not sign the informed consent.
- Mean pulmonary artery pressure after surgical treatment less than 25 mm Hg
- Age above 75 years.
- Patients with an increased risk of bleeding - including gastric ulcer and 12 duodenal ulcer in acute, hemorrhagic stroke.
- Severe coronary artery disease (unstable angina, myocardial infarction within the last 6 months).
- Acute heart failure or CHF IV in NYHA.
- Severe arrhythmias.
- Pregnancy, lactation.
- The presence of severe diseases of other organ systems that may result in death during the first year after surgery.
Key Trial Info
Start Date :
September 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2016
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT02238535
Start Date
September 1 2014
End Date
October 1 2016
Last Update
September 23 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
State Research Institute of Circulation Pathology
Novosibirsk, Russia, 630055